Navigation Links
Wild Child's 'Quit Nits' Offers a Safe, Natural Alternative to Current Toxic Head Lice Products
Date:1/31/2008

Preston in Margaret River, Australia, following the unpleasant discovery that her youngest daughter had head lice. After consulting a local pharmacist, Preston was shocked to learn that the most common head lice treatment was a shampoo containing toxic chemicals that can cause illness and even death. Surprisingly, not a single natural treatment was available.

After a period of intensive research, Preston developed a prototype of a product (subsequently called "Quit Nits") which used entirely natural plant oils (Quassia amara -- a shrub or small tree of which extracts of the bark contain quassinoids used as insecticides and Eucalyptus globulus -- an evergreen tree, one of the most widely cultivated trees native to Australia) to deliver highly effective results. Being a recently separated mother of three children without financial support and wanting to be available for her children, she decided to set up a home-based business to manufacture and distribute the natural head lice treatment she had first developed for her daughter. Thus, in the living room of her home, Wild Child was born.

While just completing its first weeks of availability in the U.S., Wild Child is one of the most successful natural health companies in Australia, and a global pharmaceutical operation which sells its products in Australia, Europe and the Middle East. In addition, Preston just won the 2007 Telstra Australian Business Woman of the Year award, a further testament to the company's success. With a U.S. pharmacy distribution deal, Wild Child hopes to gain a 20 percent share of the $100 million dollar OTC head lice treatment market within its first 12 months of operation. In addition, within the next two years the company will attempt to raise $40-$50 million through an initial public offering on the Australian Securities Exchange.

About Wild Child

Wild Child is about the design and development of all natural health care products for the whole family. The Wild Chi
'/>"/>

SOURCE Wild Child
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Nick Childs Joins Grey New York as Director of Content Development
2. MedeFile Materially Strengthens Balance Sheet Through Equity Financing and Debt Conversion Totaling $4 Million
3. Determined to Quit Week to Help Pennsylvanians Follow Through With Resolutions to Stop Using Tobacco
4. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
5. Equity Research Firm Issued Unauthorized Report and Press Release on Immunosyn Corporation Today
6. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
7. MB Software Corporation Reaches Agreement with Keystone Equity Partners
8. QUITPLAN(R) Services Can Help Minnesotans Kick Tobacco Habit for New Year
9. Private Equity Firms Acquire American Laser Centers
10. HealthCentral.coms New Stop Smoking Site Provides Expert Advice, Supportive Community to Help Smokers Quit
11. Studies of 20,000 smokers show quit rates double with counseling and free nicotine patches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2008)...t. 5 /PRNewswire/ -- EthicAd, a nonprofit organiza...nsumer education, announces,the launch of a new FD...er,understand direct-to-consumer (DTC) advertising...About Prescription Drug Advertising," is,hosted by... and was,developed by the FDA in partnership with ...
(Date:9/5/2008)...Women with hormone-receptor positive, metastatic b...p keep their cancer at bay, but when the tumor bec...ith chemotherapy becomes the only option. But a st... Symposiummay change this approach. Early data su... the tumor, allowing anti-hormonal drugs to do the...
(Date:9/4/2008)..., September 5, 2008Private Medicare Advantage (MA)...er enrollee in 2008 compared to what the same enro...ee-for-service program, according to a new report ...eductions to MA plans mandated by the Medicare Imp...MIPPA) scheduled to take effect beginning in 2010...
(Date:9/4/2008)...tronger labeling about fungal infection risk , ...deral health authorities have asked the manufactur... bolster safety warnings on the risk of developing...Humira, Cimzia, Enbrel and Remicade, belong to a c... alpha blockers (TNF-alpha blockers), which suppre...
Breaking Medicine News(10 mins):Health News:Prescription Drug Advertising Subject of New FDA Web Site for Consumers 2Health News:1 step back ... 2 steps forward 2Health News:Extra payments to Medicare Advantage plans to total $8.5 billion in 2008 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 2Health News:FDA Demands Tougher Warnings on Immunosuppressive Drugs 3
...from Norwegian Radium Hospital and National Hospit... many cancer Institutes has presented their study ...nd that // long use of Non-steroidal Anti-inflamma...cer in smoking individuals by at least 50%. But th...
...lion people worldwide are estimated to suffer from...se of neurological disability in young adults, and...f life. // Currently marketed therapies afford an ...30% in two-year studies and require frequent injec...
...loning has been a dream come true for the scientis...od and Drug Administration is expected to take an ...that milk // from cloned animals, as well as their...olds the credit when it comes to cloning technique...
...ery could finally prove to be an answer for the pr...e. Surgical treatment of prostate cancer with robo...ring and a // reduction in the post-operative comp...nd leading cause of death among American men. The ...
Other Medicine News:Health News:NSAIDS, Reduces The Risk Of Oral Cancer But Causes Heart Attacks 2Health News:New Hope For Patients With Relapsing Multiple Sclerosis 2Health News:Complete Robotic Surgery To Revolutionize Surgical Treatment of Prostate Cancer 2
(Date:9/3/2008)... The American College of Rheumatology Research ...ign Yields Significant Advances in Detecting, ...LANTA, Sept. 3 /- For the first time ... for rheumatoid arthritis, the,American College of...,releasing new information acquired from research ...
(Date:9/3/2008)... September is National Vascular Diseas.../- Diffusion Pharmaceuticals,LLC, a c...zing new drugs,for the treatment of unmet medical ... patients in a Phase I/II clinical trial of its le...The trial, designated NCT00725881,on the clinicalt...
(Date:9/3/2008)... GAITHERSBURG, Md., Sept. 3 /- P...ssuance of U.S. Patent Number 7,413,737 covering,a...a-hydroxylase (HAAH), a,proprietary human cancer b...were developed in collaboration with the Massachus... exclusive, worldwide rights to this patent,for de...
(Date:9/3/2008)... Company to Discuss Phase 3 Plan... -- Agile Therapeutics, Inc.,announced today that... in,the development of the company,s new, innovati...ch the company refers to by its internal product,c...udy successfully met its,primary endpoint of ovula...
Breaking Medicine Technology:New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 2New Research Shows Promise for Finding A Cure for Rheumatoid Arthritis 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 2Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 3Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies 4Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 2Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 3Agile Therapeutics Achieves Phase 2 Study Endpoints in Key Clinical Trials with New, Innovative Low-Dose Contraceptive Patch 4AstraZeneca Submits sNDA for NEXIUM 28R 29 I V for Peptic Ulcer Bleed Indication 2234 1AstraZeneca Submits sNDA for NEXIUM 28R 29 I V for Peptic Ulcer Bleed Indication 2234 2AstraZeneca Submits sNDA for NEXIUM 28R 29 I V for Peptic Ulcer Bleed Indication 2234 3AstraZeneca Submits sNDA for NEXIUM 28R 29 I V for Peptic Ulcer Bleed Indication 2234 4AstraZeneca Submits sNDA for NEXIUM 28R 29 I V for Peptic Ulcer Bleed Indication 2234 5AstraZeneca Submits sNDA for NEXIUM 28R 29 I V for Peptic Ulcer Bleed Indication 2234 6US soldiers in high tuberculosis areas face new epidemic 3A false positives 20647 1US soldiers in high tuberculosis areas face new epidemic 3A false positives 20647 2Long Term Care Insurance Leader Goes Green Targeting a Million Gallons of Gasoline Saved Per Year 20644 1Long Term Care Insurance Leader Goes Green Targeting a Million Gallons of Gasoline Saved Per Year 20644 2Long Term Care Insurance Leader Goes Green Targeting a Million Gallons of Gasoline Saved Per Year 20644 3International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India 2232 1International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India 2232 2International Diabetes Federation Grant Supports Lifestyle Intervention Study to Prevent Type 2 Diabetes in India 2232 3
...nnelly, MT (ASCP) Contributing Editor , ,Qual...to meeting the needs of doctors and patients by ve...ds. Vendors of these systems can be a valuable res...cols to help lab managers ensure that analytical e...ing suitable QC materials for today,s laboratories...
...S. Singer, M.D., Ph.D. ,Contributing Editor ,...l condition that affects 7% of individuals sometim...ppendix, a blind pouch of intestine at the proxima...mphatic tissue. Infection ensues, which can rapid...these complications, already elevated for children...
Other Medicine Technology:New Quality Control Systems for Every Laboratory Application 2New Quality Control Systems for Every Laboratory Application 3Appendicitis: Evolving Tools to Diagnose a Classic Disease 2Appendicitis: Evolving Tools to Diagnose a Classic Disease 3
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
...boratory and a worldwide leader in innovative labo...tensive test menu of highly complex and unique med...ed by the University of Utah, ARUP Laboratories' c...ersity teaching hospitals and children's hospitals...
Medicine Products: